Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Laroni

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Ebiomedicine|September 26, 2021
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapiesMaria Pia Sormani, Matilde Inglese, Irene Schiavetti, et al.
Ebiomedicine|May 8, 2022
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in ItalyMaria Pia Sormani, Irene Schiavetti, Matilde Inglese, et al.
Multiple Sclerosis and Related Disorders|March 26, 2020
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian studyGiorgia T Maniscalco, Francesco Saccà, Roberta Lanzillo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2018
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life studyFrancesco Saccà, Roberta Lanzillo, Alessio Signori, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 18, 2020
Cladribine vs other drugs in MS: Merging randomized trial with real-life dataAlessio Signori, Francesco Saccà, Roberta Lanzillo, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Ebiomedicine|September 26, 2021
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapiesMaria Pia Sormani, Matilde Inglese, Irene Schiavetti, et al.
Ebiomedicine|May 8, 2022
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in ItalyMaria Pia Sormani, Irene Schiavetti, Matilde Inglese, et al.
Multiple Sclerosis and Related Disorders|March 26, 2020
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian studyGiorgia T Maniscalco, Francesco Saccà, Roberta Lanzillo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2018
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life studyFrancesco Saccà, Roberta Lanzillo, Alessio Signori, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 18, 2020
Cladribine vs other drugs in MS: Merging randomized trial with real-life dataAlessio Signori, Francesco Saccà, Roberta Lanzillo, et al.
Pageof 8